Time New York: Mon 25 Jun 01:55 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

ABIOMED (ABMD) Banks on Impella Platform, Competition Rife

Zacks

On Mar 12, we issued an updated research report on ABIOMED, Inc. ABMD, a leading medical product developer. The stock carries a Zacks Rank #3 (Hold). The company's robust demand for the Impella product line has been the key growth catalyst. However, stiff competition adds to the woes.

Impella, ABIOMED’s flagship product line, has continued to be growth driver. Impella is the world's smallest heart pump. It is a support system of percutaneous, catheter-based devices offering hemodynamic support to the heart. The platform reflected stellar performance in the third quarter.

The market is upbeat about ABIOMED’s flagship Impella 2.5 and Impella CP heart-pumps receiving Pre-Market Approval (PMA) from the FDA for expanded use. To note, the Impella support has already been integrated in hospitals throughout Germany and Japan.


Also, ABIOMED recently announced expanded FDA Pre-Market Approval (PMA) for its flagship Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps.

In the past year, ABIOMED has returned 144.5% outperforming the S&P 500’s 18% gain over the same time frame. The current level is also better than the industry's growth of 27.6%.

Competition among treatment providers for heart-related diseases is intense and is subject to rapid technological change, and evolving industry requirements and standards. ABIOMED’s products compete with a temporary cardiac assist device from Throated, which was acquired by St. Jude. The company also faces stiff competition from organizations developing permanent heart assist products.

Of the other major headwinds, ABIOMED is likely to face increasing pricing pressure due to growing competitionin its key markets. Also, stretched valuation and currency fluctuations add to the woes.

Key Picks

A few better-ranked stocks in the broader medical sector are PerkinElmer PKI, Bio-Rad Laboratories BIO and athenahealth, Inc. ATHN.

PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).

Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.

athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.